I tend to agree with your decision to let the Medivir unrealized gains ride, even though I’m betting on a different horse (ENTA). If GILD doesn’t take the whole market the way many investors and analyst think they will, there ought to be plenty of upside for both of us.
Market Data 
Markets 
AI
